Overview

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Status:
Completed

Trial end date:
2021-04-19

Target enrollment:

Participant gender:

Summary

The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Darbepoetin alfa
Prolyl-Hydroxylase Inhibitors